294 related articles for article (PubMed ID: 30872370)
1. Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis.
Gordeuk VR; Key NS; Prchal JT
Haematologica; 2019 Apr; 104(4):653-658. PubMed ID: 30872370
[TBL] [Abstract][Full Text] [Related]
2. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis.
Ruggeri M; Tosetto A; Frezzato M; Rodeghiero F
Ann Intern Med; 2003 Sep; 139(6):470-5. PubMed ID: 13679323
[TBL] [Abstract][Full Text] [Related]
3. Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera.
Nguyen E; Harnois M; Busque L; Sirhan S; Assouline S; Chamaki I; Olney H; Mollica L; Szuber N
Blood Cancer J; 2021 Apr; 11(4):75. PubMed ID: 33859172
[No Abstract] [Full Text] [Related]
4. Plasma homocysteine levels in 10 patients with polycythemia.
Tonon G; Boyd K; Lecchi A; Lombardi R; Porcella A; Cattaneo M
Haematologica; 1997; 82(3):343-4. PubMed ID: 9234587
[TBL] [Abstract][Full Text] [Related]
5. [New criteria for differential diagnosis of polycythemia vera and erythrocytosis].
Velik LV; Udris OIu; Bondare DK
Gematol Transfuziol; 1992; 37(9-10):40-2. PubMed ID: 1490574
[TBL] [Abstract][Full Text] [Related]
6. Polycythemia Vera.
Spivak JL
Curr Treat Options Oncol; 2018 Mar; 19(2):12. PubMed ID: 29516275
[TBL] [Abstract][Full Text] [Related]
7. Laboratory investigations and prediction of thrombotic risk in polycythemia vera.
Boneu B
Nouv Rev Fr Hematol (1978); 1994 Apr; 36(2):183-5. PubMed ID: 8036139
[TBL] [Abstract][Full Text] [Related]
8. Cyanotic congenital heart disease (CCHD) with symptomatic erythrocytosis.
Rose SS; Shah AA; Hoover DR; Saidi P
J Gen Intern Med; 2007 Dec; 22(12):1775-7. PubMed ID: 17917783
[TBL] [Abstract][Full Text] [Related]
9. [Characteristics of diagnostic approach to erythrocytosis of different genesis].
Ter Arkh; 2012; 84(4):29-35. PubMed ID: 22774487
[TBL] [Abstract][Full Text] [Related]
10. The efficiency of therapeutic erythrocytapheresis compared to phlebotomy: a mathematical tool for predicting response in hereditary hemochromatosis, polycythemia vera, and secondary erythrocytosis.
Evers D; Kerkhoffs JL; Van Egmond L; Schipperus MR; Wijermans PW
J Clin Apher; 2014 Jun; 29(3):133-8. PubMed ID: 24130064
[TBL] [Abstract][Full Text] [Related]
11. Determination of serum immunoreactive erythropoietin in the investigation of erythrocytosis.
Cotes PM; Doré CJ; Yin JA; Lewis SM; Messinezy M; Pearson TC; Reid C
N Engl J Med; 1986 Jul; 315(5):283-7. PubMed ID: 3724821
[TBL] [Abstract][Full Text] [Related]
12. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
Alvarez-Larrán A; Pérez-Encinas M; Ferrer-Marín F; Hernández-Boluda JC; Ramírez MJ; Martínez-López J; Magro E; Cruz Y; Mata MI; Aragües P; Fox ML; Cuevas B; Montesdeoca S; Hernández-Rivas JA; García-Gutiérrez V; Gómez-Casares MT; Steegmann JL; Durán MA; Gómez M; Kerguelen A; Bárez A; García MC; Boqué C; Raya JM; Martínez C; Albors M; García F; Burgaleta C; Besses C;
Haematologica; 2017 Jan; 102(1):103-109. PubMed ID: 27686377
[TBL] [Abstract][Full Text] [Related]
13. Erythrocytosis: Diagnosis and investigation.
Noumani I; Harrison CN; McMullin MF
Int J Lab Hematol; 2024 May; 46 Suppl 1():55-62. PubMed ID: 38695361
[TBL] [Abstract][Full Text] [Related]
14. JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views.
Gangat N; Szuber N; Pardanani A; Tefferi A
Leukemia; 2021 Aug; 35(8):2166-2181. PubMed ID: 34021251
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular events and intensity of treatment in polycythemia vera.
Marchioli R; Finazzi G; Specchia G; Cacciola R; Cavazzina R; Cilloni D; De Stefano V; Elli E; Iurlo A; Latagliata R; Lunghi F; Lunghi M; Marfisi RM; Musto P; Masciulli A; Musolino C; Cascavilla N; Quarta G; Randi ML; Rapezzi D; Ruggeri M; Rumi E; Scortechini AR; Santini S; Scarano M; Siragusa S; Spadea A; Tieghi A; Angelucci E; Visani G; Vannucchi AM; Barbui T;
N Engl J Med; 2013 Jan; 368(1):22-33. PubMed ID: 23216616
[TBL] [Abstract][Full Text] [Related]
16. Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.
Kremyanskaya M; Kuykendall AT; Pemmaraju N; Ritchie EK; Gotlib J; Gerds A; Palmer J; Pettit K; Nath UK; Yacoub A; Molina A; Saks SR; Modi NB; Valone FH; Khanna S; Gupta S; Verstovsek S; Ginzburg YZ; Hoffman R;
N Engl J Med; 2024 Feb; 390(8):723-735. PubMed ID: 38381675
[TBL] [Abstract][Full Text] [Related]
17. Idiopathic erythrocytosis: a disappearing entity.
McMullin MF
Hematology Am Soc Hematol Educ Program; 2009; ():629-35. PubMed ID: 20008248
[TBL] [Abstract][Full Text] [Related]
18. The classification and diagnosis of erythrocytosis.
McMullin MF
Int J Lab Hematol; 2008 Dec; 30(6):447-59. PubMed ID: 18823397
[TBL] [Abstract][Full Text] [Related]
19. ST-Segment Elevation Myocardial Infarction and Bleeding Complications in JAK2-Negative Polycythemia.
Duran Luciano P; Sabella-Jiménez V
Tex Heart Inst J; 2023 Oct; 50(5):. PubMed ID: 37872693
[TBL] [Abstract][Full Text] [Related]
20. Polycythemia Vera: Rapid Evidence Review.
Fox S; Griffin L; Robinson Harris D
Am Fam Physician; 2021 Jun; 103(11):680-687. PubMed ID: 34060791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
